Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Fungal Infection Reports
Published in: Current Fungal Infection Reports 4/2017

01-12-2017 | Clinical Mycology Lab Issues (S Córdoba, Section Editor)

Onychomycoses in a Military Population in Brazil

Authors: Larissa Lopes Milane Bentine, Lucas Xavier Bonfietti, Maria Walderez Szeszs, Marcia de Souza Carvalho Melhem

Published in: Current Fungal Infection Reports | Issue 4/2017

Login to get access

Abstract

Purpose of Review

This study aimed to isolate and characterize filamentous fungi onychomycosis agents in a military population assisted at a hospital outpatient clinic.

Recent Findings

In onychomycosis, the fungi colonize the subungual region causing thickening, discoloration, or cracking of the nail bed. Samples were collected from patients with clinical sights of onychomycosis.

Summary

Among 80 samples collected, 50 (62.5%) had positive culture. Isolated dermatophytes (86%) were Trichophyton rubrum (21; 42%), T. mentagrophytes var. interdigitale (19; 38%), and Microsporum gypseum (3; 6%) and non-dermatophyte molds were Fusarium spp. (1; 2%), Scytalidium spp. (1; 2%), and Chaetomium globosum (5; 10%). Minimal inhibitory concentrations (mg/L) of terbinafine, itraconazole, and fluconazole necessary to inhibit 50/90% of the isolates were respectively 0.015/0.06, 0.06/0.12, and 32/32. Etiological agents of onychomycosis in a military hospital are similar as reported in studies for the general population. High prevalence of non-dermatophytic agents was observed, especially for Chaetomium globosum.
Literature
1.
Ghannoum MA, Hajjeh RA, Scher R, Konnikov N, Gupta AK, Summerbell R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;43:641–8.CrossRefPubMed
2.
3.
4.
Katoh T. Guidelines for diagnosis and treatment of mucocutaneous candidiasis. Jpn J Med Mycol. 2009;50:207–12.CrossRef
5.
Iorizzo M, Piraccini BM, Rech G, Tosti A. Treatment of onychomycosis with oral antifungal agents. Expert Opin Drug Deliv. 2005;2:435–40.CrossRefPubMed
6.
Stüttgen G, Bauer E. Bioavailability, skin- and nailpenetration of topically applied antimycotics. Mycoses. 1982;25:74–80.CrossRef
7.
Santos DA, Barros MES, Hamdan JS. Establishing a method of inoculum preparation for susceptibility testing of Trichophyton rubrum and Trichophyton mentagrophytes. J Clin Microbiol. 2006;44:98–101.CrossRefPubMedPubMedCentral
8.
Silva Barros ME, de Assis SD, Hamdan JS. Evaluation of susceptibility of Trichophyton mentagrophytes and Trichophyton rubrum clinical isolates to antifungal drugs using a modified CLSI microdilution method (M38-A). J Med Microbiol. 2007;56:514–8.CrossRefPubMed
9.
Ameen M, Lear JT, Madan V, Mohd Mustapa MF, Richardson M. British Association of Dermatologists’ guidelines for the management of onychomycosis. Br J Dermatol. 2014;171:937–58.CrossRefPubMed
10.
Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol. 1992;126:23–7.CrossRefPubMed
11.
Aly R. Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol. 1994;31:21–5.CrossRef
12.
Scher RK, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol. 2003;149:5–9.CrossRefPubMed
13.
Segal R, Shemer A, Hochberg M, et al. Onychomycosis in Israel: epidemiological aspects. Mycoses. 2015;58:133–9.CrossRefPubMed
14.
Drakensjö IT, Chryssanthou E. Epidemiology of dermatophyte infections in Stockholm, Sweden: a retrospective study from 2005–2009. Med Mycol. 2011;49:484–8.PubMed
15.
Saunte D, Svejgaard E, Haedersdal M, Frimodt-Møller N, Jensen AM, Arendrup CM. Laboratory-based survey of dermatophyte infections in Denmark over a 10-year period. Acta Derm Venereol. 2008;88:614–6.PubMed
16.
Tchernev G, Penev PK, Nenoff P, et al. Onychomycosis: modern diagnostic and treatment approaches. Wien Med Wochenschr. 2013;163:1–12.CrossRefPubMed
17.
Dolenc-Voljc M. Dermatophyte infections in the Ljubljana region, Slovenia, 1995–2002. Mycoses. 2005;48:181–6.CrossRefPubMed
18.
Garg A, Venkatesh V, Singh M, Pathak KP, Kaushal GP, Agrawal SK. Onychomycosis in central India: a clinicoetiologic correlation. Int J Dermatol. 2004;43:498–502.CrossRefPubMed
19.
Nzenze Afene S, Ngoungou EB, Mabika Mamfoumbi M, Bouyou Akotet MK, Avome Mba IM, Kombila M. Les onychomycoses au Gabon: aspects cliniques et mycologiques. J Mycol Med. 2011;21:248–55.CrossRef
20.
Summerbell RC, Cooper E, Bunn U, Jamieson F, Gupta AK. Onychomycosis: a critical study of techniques and criteria for confirming the etiologic significance of nondermatophytes. Med Mycol. 2005;43:39–59.CrossRefPubMed
21.
Gupta AK, Cooper EA, MacDonald P, Summerbell RC. Utility of inoculum counting (Walshe and English criteria) in clinical diagnosis of onychomycosis caused by nondermatophytic filamentous fungi. J Clin Microbiol. 2001;39:2115–22.CrossRefPubMedPubMedCentral
22.
Kemna ASCP, Elewski BE. A U.S. epidemiologic survey of superficial fungal diseases. J Am Acad Dermatol. 1996;35:539–42.CrossRefPubMed
23.
Koussidou T, Devliotou-Panagiotidou D, Karakatsanis G, et al. Onychomycosis in Northern Greece during 1994–1998. Mycoses. 2002;45:29–37.CrossRefPubMed
24.
Gianni C, Cerri A, Crosti C. Non-dermatophytic onychomycosis. An underestimated entity? A study of 51 cases. Mycoses. 2000;43:29–33.CrossRefPubMed
25.
Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol. 2000;42:217–24.CrossRefPubMed
26.
Heikkila H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol. 1995;133:699–703.CrossRefPubMed
27.
Clayton YM. Clinical and mycological diagnostic aspects of onychomycoses and dermatomycoses. Clin Exp Dermatol. 1992;17:37–40.CrossRefPubMed
28.
Maraki S, Nioti E, Mantadakis E, Tselentis Y. A 7-year survey of dermatophytoses in Crete, Greece. Mycoses. 2007;50:481–4.CrossRefPubMed
29.
El Sayed F, Ammoury A, Haybe RF, Dhaybi R. Onychomycosis in Lebanon: a mycological survey of 772 patients. Mycoses. 2006;49:216–9.CrossRefPubMed
30.
Gupta AK, Jain HC, Lynde CW, Watteel GN, Summerbell RC. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists’ offices in Ontario, Canada—a multicenter survey of 2001 patients. Int J Dermatol. 1997;6:783–7.CrossRef
31.
Araújo AJG, Souza MAJ, Bastos OM, Oliveira JC. Onychomycosis caused by emergent fungi: clinical analysis, diagnosis and revision. An Bras Dermatol. 2003;78:445–55.CrossRef
32.
Brilhante RSN, Paixão GC, Salvino LK, Diógenes MJN, Bandeira SP, Rocha MFG, et al. Epidemiologia e ecologia das dermatofitoses na cidade de Fortaleza: o Trichophyton tonsurans como importante patógeno emergente da Tinea capitis. Rev Soc Bras Med Trop. 2000;33:417–25.CrossRefPubMed
33.
Costa M, Passos XS, Souza LKH, Miranda ATB, Lemos JÁ, Júnior JGO, et al. Epidemiologia e etiologia das dermatofitoses em Goiânia, GO, Brasil. Rev Soc Bras Med Trop. 2002;35:19–22.CrossRefPubMed
34.
Lacaz CS, Porto E, Melo NT. Guia para identificação: fungos, actimomicetos e algas de interesse medico. 1a edição. São Paulo: Savier; 1998.
35.
36.
Hilmioğlu-Polat S, Metin DY, Inci R, Dereli T, Kilinç I, Tümbay E. Non-dermatophytic molds as agents of onychomycosis in Izmir, Turkey—a prospective study. Mycopathologia. 2005;160:125–8.CrossRefPubMed
37.
Ramani R, Srinivas CR, Ramani A, Kumari TG, Shivananda PG. Molds in onychomycosis. Int J Dermatol. 1993;32:877–8.CrossRefPubMed
38.
Stiller MJ, Rosenthal S, Summerbell RC, et al. Onychomycosis of the toenails caused by Chaetomium globosum. J Am Acad Dermatol. 1992;26:775–6.CrossRefPubMed
39.
Rippon JW. Medical mycology: the pathogenic fungi and the pathogenic actinomycetes, 3rd ed. Philadelphia: W.B. Saunders Co.; 1988.
40.
Hattori N, Adachi M, Kaneko T, Shimozuma M, Ichinohe M, Iozumi K. Case report. Onychomycosis due to Chaetomium globosum successfully treated with itraconazole. Mycoses. 2000;43:89–92.CrossRefPubMed
41.
Naidu J, Singh SM, Pouranik M. Onychomycosis caused by Chaetomium globosum Kunze. Mycopathologia. 1991;113:31–4.CrossRefPubMed
42.
Fernández-Torres B, Carrillo AJ, Martín E, Del Palacio A, Moore MK, Valverde A, et al. In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob Agents Chemother. 2001;45:2524–8.CrossRefPubMedPubMedCentral
43.
Mukherjee PK, Leidich SD, Isham N, Leitner I, Ryder NS, Ghannoum MA. Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine. Antimicrob Agents Chemother. 2003;47:82–6.CrossRefPubMedPubMedCentral
44.
Tamura T, Asahara M, Yamamoto M, Yamaura M, Matsumura M, Goto K, et al. In vitro susceptibility of dermatomycoses agents to six antifungal drugs and evalution by fractional inhibitory concentration index of combined effects of amorolfine and itraconazole in dematophytes. Microbiol Immunol. 2014;58:1–8.CrossRefPubMed
45.
Carrillo-Muñoz AJ, Guglietta A, Palacín C, Casals J, del Valle O, Guardià C, et al. In vitro antifungal activity of sertaconazole compared with nine other drugs against 250 clinical isolates of dermatophytes and Scopulariopsis brevicaulis. Chemotherapy. 2004;50:308–13.CrossRefPubMed
46.
Yamazaki H, Nakamoto M, Shimizu M, Murayama N, Niwa T. Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. Br J Clin Pharmacol. 2010;69:593–7.CrossRefPubMedPubMedCentral
47.
Jessup CJ, Ryder NS, Ghannoum MA. An evaluation of the in vitro activity of terbinafine. Med Mycol. 2000;38:155–9.CrossRefPubMed
48.
Osborne CS, Hofbauer B, Favre B, Ryder NS. In vitro analysis of the ability of Trichophyton rubrum to become resistant to terbinafine. Antimicrob Agents Chemother. 2003;47:3634–6.CrossRefPubMedPubMedCentral
Metadata
Title
Onychomycoses in a Military Population in Brazil
Authors
Larissa Lopes Milane Bentine
Lucas Xavier Bonfietti
Maria Walderez Szeszs
Marcia de Souza Carvalho Melhem
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Fungal Infection Reports / Issue 4/2017
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-017-0291-8

Other articles of this Issue 4/2017

Current Fungal Infection Reports 4/2017 Go to the issue

Fungal Genomics and Pathogenesis (S Shoham, Section Editor))

Pathogenesis of Invasive Pulmonary Aspergillosis in Transplant Recipients

Fungal Genomics and Pathogenesis (Shmuel Shoham, Section Editor)

What Is New? Recent Knowledge on Fungal Extracellular Vesicles

Erratum

Erratum to: Harnessing Whole Genome Sequencing in Medical Mycology

Clinical Mycology Lab Issues (S Córdoba, Section Editor)

Time-Kill Curves Studies with Amphotericin B Against Cryptococcus neoformans/C. gattii Species Complex Clinical Isolates

Clinical Mycology Lab Issues (S Córdoba, Section Editor)

Candida auris: Antifungal Multi-Resistant Emerging Yeast

Clinical Mycology Lab Issues (S Córdoba, Section Editor)

Candida haemulonii sensu lato: Update of the Determination of Susceptibility Profile in Argentina and Literature Review

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits